英格兰基层医疗苯二氮䓬类药物处方模式与不良后果
该 population-level 观察性研究分析英格兰 14 种苯二氮䓬类药物的处方、费用和 ADR 数据。2020 至 2025 年总处方率从 15562.34 降至 12284.01 项/10 万人,年均变化 -4.3%(95%CI:-4.5% 至 -4.03%)。专科用药如氯巴占和咪达唑仑增加,所有 BZD 平均终生致死比为每 100 例报告 4.5 例死亡。
要点
- 总 BZD 处方率下降,主要因地西泮、替马西泮和氯氮䓬处方减少。
- 专科用药氯巴占和咪达唑仑处方增加。
- 奥沙西泮致死比最高(17.9),其次劳拉西泮(9.1)和阿普唑仑(8.6)。
核心结论
- 英格兰 BZD 处方持续下降,反映去处方政策成功,但专科用药增加、不公平现象持续及药物特异性安全和费用问题需谨慎处方和加强药物警戒。
研究设计与样本
- 人口水平观察性研究,使用国家数据集分析 14 种 BZD 的处方、费用和 ADR 数据,处方率标准化为每 10 万人,计算致死比,回归模型评估年度变化,广义加性模型分析社会经济影响。
主要发现
- 总 BZD 处方从 2020 年 15562.34 项/10 万人降至 2025 年 12284.01 项/10 万人,年均变化 -4.3%(95%CI:-4.5% 至 -4.03%)。
- 氯巴占年均变化 6.36%(95%CI:0.34% 至 12.39%),咪达唑仑 1.03%(95%CI:-1.30% 至 3.37%)。
- 所有 BZD 平均终生致死比为每 100 例报告 4.5 例死亡,奥沙西泮最高(17.9),劳拉西泮 9.1,阿普唑仑 8.6。
- 种族影响剥夺相关处方模式,表明社会经济地位之外存在差异。
临床怎么用
- 临床应关注 BZD 处方下降趋势,同时警惕专科用药增加及药物特异性致死风险,加强药物警戒并促进公平可及。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Benzodiazepines (BZDs) are commonly prescribed for anxiety and insomnia but carry risks such as dependence, adverse drug reactions (ADRs) and mortality. Despite deprescribing efforts, the influence of recent prescribing trends, COVID-19 and adverse outcomes on prescribing patterns in England remains uncertain. This study evaluates trends in BZD prescribing, costs, and safety outcomes and explores their socioeconomic associations. METHODS: This population-level observational study analysed prescribing, cost and ADR data for 14 BZDs using national datasets. Prescribing rates were standardized per 100 000 population, fatality ratios were calculated, and regression models assessed yearly changes by drug, region, and pandemic phase. Socioeconomic influences on prescribing were analysed using a generalized additive model. RESULTS: Total BZD prescribing decreased from 15562.34 items per 100 000 population in 2020 to 12284.01 in 2025, a mean annual change of -4.3% (95% CI: -4.5% to -4.03%), largely because of reduced prescribing of diazepam, temazepam and chlordiazepoxide. Conversely, specialist-use agents increased, including clobazam (6.36% per year, 95% CI: 0.34% to 12.39%) and midazolam (1.03% per year, 95% CI: -1.30% to 3.37%). Ethnicity influenced deprivation-related prescribing patterns, indicating disparities beyond socioeconomic status. The average lifetime fatality ratio across all BZDs was 4.5 deaths per 100 reported cases, with oxazepam the highest (17.9), followed by lorazepam (9.1) and alprazolam (8.6). CONCLUSIONS: Benzodiazepine prescribing in England continues to decline, reflecting successful deprescribing policies. However, increasing specialist use, persistent inequities, and drug-specific safety and cost concerns highlight the need for cautious prescribing, enhanced pharmacovigilance and equitable access.
引用
- Chaudhry A, Khan MU, Conway B, et al. Benzodiazepines use in primary care England: Prescribing patterns and adverse consequences. Br J Clin Pharmacol. 2026. PMID: 42758106. doi:10.1002/bcp.70824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。